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ristian Wachtell, MD, PHD, FACC
openhagen, Denmark
lthough the clinical phenotype of atrial fibrillation (AF)
as multiple causes, the most prevalent cause in theWestern
orld is hypertensive heart disease caused by the high
revalence of hypertension. Change in hemodynamic status
y an increase in blood pressure has many direct effects on
eft ventricular and atrial structure and function. Since the
rst report of angiotensin-converting enzyme inhibition
ACEI) in patients with acute myocardial infarction (1),
here have been numerous reports that treatment with either
CEI or angiotensin receptor blockade reduces the risk of
ew-onset AF. This has led to 2 schools of thought: that
hese agents either possess antiarrhythmic properties, which
ome studies actually suggest, or that the primary effect of
his treatment is in fact not by electrical remodeling but
ather by changing and improving the hemodynamic status
See page 24
n patients at risk for AF. This has led to several currently
ngoing studies looking at how treatment-induced hemo-
ynamic improvement affects the risk of risk new-onset AF.
urthermore, studies have also investigated whether im-
rovement of left ventricular structure (i.e., by reduced left
entricular hypertrophy) (2) and function reduces the risk of
F. Finally, a few studies have recently investigated whether
eduction in left atrial structure (size) and improvement in
eft atrial function can reduce the risk of AF. The clinical
mplication has moved focus away from treating AF with
eta-receptor blockers as well as conventional antiarrhyth-
ic drugs; the latter treatment has turned out to be quite
ifficult because of side effects. The new approach is to
tilize existing treatment known to improve patients’ he-
odynamic status by reducing central blood pressure, re-
ucing left ventricular mass, improving left ventricular
ystolic function, reducing left atrial size, and improving left
trial function.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.o
From Rigshospitalet, Department of Medicine B, The Heart Center, Copenhagen,
enmark.If one believes in this hemodynamic hypothesis, a logical
onsequence is that AF is in fact not lone but should be
onsidered as target organ damage of impaired hemody-
amic status, increased blood pressure, inappropriate left
entricular hypertrophy, and left atrial size as well as
mpaired left ventricular and atrial function. Examples of
F during changed hemodynamic status have been reported
n young people on drinking sprees or during strenuous
xercise, in which large volume changes occur. However, in
ore mature patients, episodes of AF are more likely to be
aused by impaired hemodynamic status attributable to
ncreased blood pressure, just by the a priori risk of
ypertensive disease in elderly patient populations. There-
ore, a clinical strategy, if we have done our best to find any
ther causative disease of AF, could be to conclude that
lood pressure for this individual is too high and must be
rought down to improve the patient’s hemodynamic status.
This action could also be justified by the clinical problem
f relating an individual patient’s blood pressure to that of
roups of normal subjects. When the clinician determines
hether any given patient is hypertensive, blood pressures
re most often related to so-called normal values (i.e.,
40/90 mm Hg). However, in an individual patient it is
lways unknown whether blood pressure just precedes our
efinition of hypertension and blood pressure is increased
or that patient. Prediction models predict that increased
ystolic blood pressure by 10-mm Hg increases the risk of
F independent of age, sex, and any given level of electro-
ardiographic left ventricular hypertrophy (3). A logical but
till undocumented consequence would be that an increase
f systolic blood pressure in the normal range would also
ncrease the risk of AF. However, if AF per se were
onsidered target organ damage, a given patient with systolic
lood pressure over 120 mm Hg would by definition be
onsidered hypertensive and treatment should be initiated at
uch lower values than currently recommended. The current
uropean Society of Cardiology/European Society of hyper-
ension Guidelines on treating hypertension (4) has already in
art taken these considerations into account, as patients
ith an associated clinical condition (i.e., acute myocardial
nfarction, stroke, or renal impairment) should have antihy-
ertensive treatment initiated if systolic blood pressure
xceeds 120 mm Hg. In addition, the guidelines now
uggest that systolic blood pressure between 130 and 139
m Hg should also be treated with concomitant AF.
The study by Belluzzi et al. (5) in this issue of the Journal
s an interesting study that in a standardized fashion
valuates whether ramipril is able to prevent recurrent
pisodes of so-called lone AF. The study shows that the
lacebo-treated patients have a more than 3-fold increased
isk of recurrent lone AF compared with the active treat-
ent with ramipril. One obvious limitation of the study is
he small sample size. However, patients with lone AF, if it
xists as a disease entity, are rare and few. The importance
f the current study is that it suggests that improvement of
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December 30, 2008/January 6, 2009:30–1 Lone AF?he hemodynamic status in patients with systolic blood
ressures between 130 and 139 mm Hg and normal left
trial or ventricular structure and function does reduce
atients’ risk of future new-onset AF. Thus, this study
urther supports the idea that AF is a marker of target-organ
amage even with normal systolic blood pressure and substan-
iates the thoughts that treatment should be initiated even
ith normal or high-normal systolic blood pressure if AF is
resent. Furthermore, the fact that some patients random-
zed to placebo also became hypertensive during the study is
lso a clue indicating that AF in an individual patient just
recedes our definition of hypertension and is a marker of
arget organ damage by reflecting an impaired hemody-
amic state.
One major piece of missing information in the study by
elluzzi et al. (5) is nonavailable data on time-varying blood
ressure. It would be of great interest to investigate how
uch additional effect the ACEI ramipril has on reducing
he risk of AF beyond its blood pressure-lowering effect.
his would indicate the ACEI composite efficacy of hemo-
ynamic improvement on central blood pressure as well as
irect ACEI improvement in left ventricular and left atrial
tructure and function. The CAFÉ (Conduit Artery Function
valuation) study (6), a substudy from ASCOT (Anglo-
candinavian Cardiac Outcomes Trial), showed that the com-
ination of perindopril/amlodipine resulted in significant
mprovement in central blood pressure compared with the
eta-blocker/diuretic combination, although the 2 treat-
ent arms had similar brachial blood pressures. If one
ccepts the hemodynamic approach to treating AF and that
ifferences in central blood pressure are essential to reducing
he risk of new-onset AF, beta-blockade may not always be
natural choice (3). Although beta-blockade does reduce
lood pressure and by this hemodynamic effect will reduce
he risk of AF, the central blood pressure is not reduced, and
s a result reoccurrences of AF are frequent. In addition,
eta-blockade may also have other detrimental effects
hrough its heart rate reducing properties in patients in sinus
K
Ahythm and normal left ventricular function treated for the
revention of paroxysmal AF. Beta-blockade also will tend
o increase atrial wall stress and may thereby promote AF
aused by increased left ventricular stroke volume during
eart rate reduction while maintaining cardiac output.
These thoughts lead to the conclusion that AF should be
onsidered a marker of target organ damage with impaired
emodynamics. Treating AF, whether lone or not, also
ncludes reduction in cardiovascular risk by using treatments
or known cardiovascular risk factors such as reducing blood
ressure, improving central hemodynamics, and reducing
eft ventricular and atrial structure and function.
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